 |
|
Mark Mulligan, M.D.
Grants
| Co - Investigator |
|
Mark Mulligan, M.D. |
| Source |
NIH/NIAID U01 AI69418 (Lennox) |
| Project Dates |
01/01/07 - 12/31/14 |
| Title of
Project |
Units for HIV/AIDS Clinical Trials Networks (CTU) - Administrative Core |
| Co - Investigator |
|
Mark Mulligan, M.D. |
| Source |
NIH/NIAID U01 AI69418 (Lennox) |
| Project Dates |
01/01/07 - 12/31/14 |
| Title of
Project |
Units for HIV/AIDS Clinical Trials Networks (CTU) - HIV Vaccine Trials Unit (HVTU) |
| Co - Investigator |
|
Mark Mulligan, M.D. |
| Source |
NIH/NIAID 1 U19 057266 (Ahmed) |
| Project Dates |
09/30/03 - 03/31/08 |
| Title of
Project |
Vaccine Induced Immunity in the Young and Aged -Clinical Core B |
| Co - Investigator |
|
Mark Mulligan, M.D. |
| Source |
NIH/NIAID 1 U19 AI61728-01 (Feinberg) |
| Project Dates |
09/2/04 - 08/31/09 |
| Title of
Project |
Optimizing the Immunogenicity of MVA-Based AIDS Vaccine |
| Co - Investigator |
|
Mark Mulligan, M.D. |
| Source |
NIH/NIAID P30 AI 50409-07 (Curran) |
| Project Dates |
8/01/05-7/31/08 |
| Title of
Project |
Emory/Atlanta Center for AIDS Research: CFAR Clinical Research Core |
| Principal Investigator |
|
Mark Mulligan, M.D. |
| Source |
Sanofi Pasteur, Inc. (Mulligan and Eidex) |
| Project Dates |
01/30/06 - 12/30/07 |
| Title of
Project |
Randomized Controlled Double-Blind Trial of the Comparative Viremia, Immunogenicity and Safety of a Comparative Viremia, Immunogenicity and Safety of a 17-D Live Attenuated Yellow Fever Vaccine (YF-VAX) Given Alone or in Combination with Human ImmunuoGlobulin (BAYGAM) |
| Co - Investigator |
|
Mark Mulligan, M.D. |
| Source |
Merck, Inc. V520 Protocol 023-01 (del Rio) |
| Project Dates |
01/13/05 - 01/13/ |
| Title of
Project |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase II Proof-of-Concept Study to Evaluate the Safety and Efficacy of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Vaccine gag/pol/nef (MRKAd5 HIV-1gag/pol/nef) in Adults at High Risk of HIV-1 Infection |
| Principal Investigator |
|
Mark Mulligan, M.D. |
| Source |
Merck, Inc. V520 Protocol 027 (Mulligan) |
| Project Dates |
10/1/06 - 12/31/08 |
| Title of
Project |
A Phase IIa Dose Refinement Study of the Safety and Immunogenicity of a 3-Dose Regimen of the Merck : Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine in Healthy Adults |
| Co - Investigator |
|
Mark Mulligan, M.D. |
| Source |
NIH/NIAID HVTN Protocol 072 (Edupuganti) |
| Project Dates |
|
| Title of
Project |
A Phase 1B clinical trial to evaluate the safety and immunogenicity of recombinant adenoviral serotype 35 (rAd35) and serotype 5 (rAd5) HIV-1 vaccines when given in heterologous prime-boost regimens or as a boost to a recombinant DNA vaccine in healthy, HIV-1-uninfected adult participants with pre-existing immunity to adenovirus serotype 5 infection |
| Principal Investigator |
|
Mark Mulligan, M.D. |
| Source |
Pending NIH/NIAID RFP NIH-NIAIDS-DMID-08-03 -(Mulligan) |
| Project Dates |
11/1/07 - 10/31/14 |
| Title of
Project |
Vaccine and Treatment Evaluation Units: Evaluation of Control Measures Against Diseases other than AIDS |
| Co - Investigator |
|
Mark Mulligan, M.D. |
| Source |
Pending NIH/NIAID U01 AI068614 (Corey) |
| Project Dates |
6/1/06-5/31/13 |
| Title of
Project |
HIV Vaccine Trials Network (HVTN) Leadership Group |
 Bio
Publications
Grants
|
|
|
 |
 |
 |
